• Explore /
  • Poster
  • / TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)<span style="color: #1a1a1a; font-family: Helvetica; font-size: x-large;" size="5" color="#1a1a1a" face="Helvetica"></span>—<span style="color: #1a1a1a; font-family: Helvetica; font-size: x-large;" size="5" color="#1a1a1a" face="Helvetica"></span>First interim analysis (IA).

TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)—First interim analysis (IA).

Abstract Poster

Authors

null

Johann S. De Bono

The Royal Marsden NHS Foundation Trust, London, United Kingdom

Johann S. De Bono , Niven Mehra , Celestia S. Higano , Fred Saad , Consuelo Buttigliero , Marielena Mata , Hsiang-Chun Chen , Cynthia G. Healy , M. Luisa Paccagnella , Akos Czibere , Karim Fizazi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03148795

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 119)

Abstract #

119

Poster Bd #

E21

Abstract Disclosures

Similar Posters

First Author: Johann S. De Bono

First Author: Neeraj Agarwal

First Author: Neeraj Agarwal

First Author: Niven Mehra